Plain-English translation of NCT06574126 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing ciltacabtagene autoleucel, a type of immune cell therapy called CAR-T, combined with chemotherapy in people with high-risk smoldering multiple myeloma. The goal is to see if treating the disease early—before it becomes fully active—can eliminate cancer cells and potentially cure the disease. The medication works by reprogramming your own immune cells to recognize and attack myeloma cells.
Smoldering myeloma is an early stage of blood cancer that is not yet requiring treatment, but some patients have high-risk features that predict it will progress quickly. This trial is exploring whether treating these high-risk patients early with this new immune cell therapy could prevent progression and possibly offer a cure, rather than waiting for the disease to become active.
You likely qualify if…
You likely don't qualify if…
You will be assigned to one of two groups that differ slightly in the order of treatments. Both groups will receive up to 2 cycles of combination chemotherapy, followed by a procedure where your immune cells are collected (apheresis), processed in a laboratory, and then returned to your body as the CAR-T cell therapy. You will then be monitored closely with blood tests and bone marrow samples to check how well the treatment is working, with follow-up visits continuing for up to 5 years after the infusion.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Spain